About: http://data.cimple.eu/news-article/80128634628ce233b43474f99c13f39de8aba12bb62e27a4c999745a

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/80128634628ce233b43474f99c13f39de8aba12bb62e27a4c999745a Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	US biotech company Moderna announced Covid vaccine is 90 percent effective against all forms of the disease and 95 percent effective against severe disease. The new results come from its ongoing Phase 3 clinical trial involving more 30,000 people across the United States, and the headline efficacy figure is a slight decrease from an earlier figure of 94.1 percent published in the New England Journal of Medicine in December. The new number is based on 900 adjudicated cases of Covid from the study as of April 9, while the previous was based on 185 cases. A company press release did not indicate why efficacy has fallen, but one reason might be the emergence of new variants of concern which are not as susceptible to antibodies evoked to the vaccine. Moderna is working on two variant-specific boosters, and said mice studies showed they elicited an increased immune response. The results of these studies have been posted online in a scientific paper that is now awaiting peer review. "The new preclinical data on our variant-specific vaccine candidates give us confidence that we can proactively address emerging variants," said CEO Stephane Bancel. The company said that as of April 12, it has delivered 132 million doses of its vaccine globally, including approximately 117 million doses to the United States. It remains on course to deliver its second tranche of 100 million doses by the end of May followed by 100 million more by the end of July. The company's clinical trial for adolescents aged 12 to 17 is now fully enrolled with 3,000 US participants, and its pediatric trial for children aged six months to 11 years is continuing to enroll its 6,750 participants in the United States and China. ia/
schema:headline	Moderna Covid vaccine efficacy falls slightly to 90% in US trial
schema:mentions	Pediatrics Clinical trial New England Antibody Ia (cuneiform) Chief executive officer Coronavirus disease Vaccine United States China Case law Tranche
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-04-13 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	86 (xsd:integer)

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software